PressReleases

Press Releases

Kineta Press Releases
Kineta to Present at JMP Securities Hematology and Oncology Summit
Seattle, WA — (November 29, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
Seattle, WA – (November 15, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation
Kineta Announces Effectiveness of Registration Statement on Form S-4 in Connection with Proposed Reverse Merger with Yumanity Therapeutics (YMTX)
Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 BOSTON, Nov. 10,
Kineta to Present at Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
Seattle, WA — (October 27, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development
Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Cancer Patients with Advanced Solid Tumors
Kineta’s VISTA blocking immunotherapy KVA12123 (formerly referred to as KVA12.1) to be evaluated in patients with advanced solid tumors Clinical
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy
Seattle, WA – (October 12, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development
Kineta Announces Participation in Upcoming October 2022 Investor Conferences
Seattle, WA – (October 10, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development
Kineta Appoints Keith Baker as Chief Financial Officer
Seattle, WA — (October 4, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development
Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium
Seattle, WA — (September 14, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.